Expertise in
127
conditions

Tao A. Yang

#300 Guangzhou Road, 
Nanjing, CN 
Expertise in
127
conditions
#300 Guangzhou Road, 
Nanjing, CN 

Overview

Tao Yang practices practicing medicine in Nanjing, China.

Yang is highly rated in 127 conditions, according to our data. Their clinical expertise encompasses Hypertension, Osteogenesis Imperfecta, Type 2 Diabetes (T2D), Splenectomy, and Laminectomy.

They are actively involved in clinical research, co-authoring 3631 peer reviewed articles and participating in 6 clinical trials.

Locations

#300 Guangzhou Road, Nanjing, 210029, China
Other Locations
81 Meishan Road, Hefei, 230032, China
2666 Ludang Road, Suzhou, 215200, China
No. 1 Minde Road, Nanchang, China
26 Yuancun Erheng Road, Guangzhou, 510655, China
No 71 Baoshan North Road, Guiyang, 550001, China
209 Tongshan Road, Xuzhou, 221004, China
No. 358 Datong Road, Pudong, 200137, China
58 Zhongshan No. 2 Road, Guangzhou, 510080, China
600 South Wan Ping Road, Shanghai, 200030, China
89 Guhuai Road, Jining, 272000, China
17 Lujiang Road, Hefei, China
No. 406 Jiefang South Rd, Dayingmen, 300211, China
No. 19A Yuquan Road, Yuquan, 100049, China
498 South Shaoshan Road, Changsha, 410004, China
1023 Shatai South Road, Guangzhou, 510515, China
168 Changhai Road, Yangpu, 200433, China
289 Kuocang Road, Lishui, 323000, China
299 Bayi Road, Wuhan, 430072, China
No. 500 Dongchuan Road, Shanghai, 200241, China
106 Nanjing Road, Qingdao, 266071, China
No. 174 Shazheng Street, Chongqing, 400044, China
No. 2800 Gongwei Road, Pudong, 201399, China
Science And Technology Park, Guangzhou, China
Science And Technology Park, Guangzhou, 510006, China
1 Xinsi Road, Xi'an, 710032, China
Pr, Shanghai, China
Yan Ta West Road 76, Xi'an, 710061, China
1037 Luoyu Road, Wuhan, 430074, China
Qingchun Road 79, Hangzhou, 310003, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug
Study Drug: Rituximab
Study Phase: Phase 4
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: March 29, 2021
Intervention Type: Drug
Study Phase: Phase 3
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

3629 Total Publications

Lamprey 3D single-cell transcriptomics reveals ancestral and specialized features of the vertebrate brain.
Lamprey 3D single-cell transcriptomics reveals ancestral and specialized features of the vertebrate brain.
Journal: Science (New York, N.Y.)
Published: June 18, 2026

Frequently Asked Questions about Tao A. Yang

Is Tao A. Yang a top-rated expert for Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Tao A. Yang is classified as an Elite expert for Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tao A. Yang participate in research or clinical trials?

Yes. Tao A. Yang has published 3629 articles and abstracts on conditions like Hypertension. You can view a list of Tao A. Yang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yang's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 109 Advanced Conditions
View All 308 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile